The Swiss pharmaceutical giant announces the acquisition of the biotech company to strengthen its pipeline in precision medicine.
Novartis has confirmed its agreement to acquire Tourmaline Bio for $1.4 billion. This move aims to bolster Novartis' capabilities in precision medicine, aligning with its strategic growth objectives. The deal reflects the growing trend of large pharma companies expanding through acquisitions of biotech firms to enhance their research and development pipeline.